HGH Fragment 176-191 5 mg vial dosage

What HGH Fragment 176-191 is

Class:

Synthetic 16-amino-acid peptide, the unmodified 176-191 C-terminal sequence of human growth hormone

Also called:

Fragment 176-191, Frag 176-191, HGH Frag, hGH 176-191

Used for:

Sold to consumers as a research-chemical fat-loss product, marketed on the claim that this slice of growth hormone carries its fat-metabolising activity without the growth-promoting or blood-sugar effects of the whole hormone. Never developed into an approved drug under this exact sequence.

Human evidence:

Animal / lab only. The only peptide from this region of hGH to reach a randomised human obesity trial is AOD-9604 - a related but different molecule (177-191 plus an added tyrosine). I could not locate any published human trial of the unmodified 176-191 sequence sold under this name. What exists is a 1978 rat study of this and other C-terminal hGH fragments, which found a hyperglycemic and insulin-raising effect rather than a fat-loss one, and a 2022 laboratory study pairing it with a cancer drug in cell culture - unrelated to weight loss. That is animal and in-vitro data only, with no human evidence at all for the fat-loss claim it is marketed on.

US status:

Unapproved drug. Not FDA-approved for any indication in the United States, and not a dietary supplement. "HGH Fragment 176-191" does not appear by that name on FDA's bulk drug substances compounding-risk page. The related, more commonly reviewed sequence is AOD-9604 (177-191 plus an added tyrosine), which FDA does list, in the "nominated but withdrawn" table, with its own immunogenicity, impurity and adverse-event concerns - a listing that does not extend to the unmodified 176-191 sequence sold under this separate name.

The full picture, with every study: HGH Fragment 176-191 guide.

How to mix a 5 mg HGH Fragment 176-191 vial

For this vial: 1 mL of bacteriostatic water makes 5 mg/mL, so 350 mcg is 7 units (0.07 mL) on a U-100 insulin syringe. Pick a different volume from the units table if you want bigger or smaller draws; the number of doses stays the same.

1. Wipe the rubber stoppers of both the peptide vial and the bacteriostatic water vial with an alcohol swab and let the alcohol dry. ^[3][4]
2. With a new sterile needle and syringe, draw up the amount of bacteriostatic water you have chosen for the dilution. ^[3][4][5]
3. Inject the water into the peptide vial by aiming the stream against the inside glass wall, which helps prevent foaming. ^[6]
4. Swirl or roll the vial gently until the powder has fully dissolved; do not shake it. Do not inject the solution if it is cloudy or has particles in it. ^[3][4][6]
5. Label the vial with the date and time it was mixed, the amount of water added and how long it can be used after mixing. ^[3]
6. Store the mixed vial in the refrigerator at 2-8°C (36-46°F) and do not freeze it. ^[6]

Step by step with pictures: how to reconstitute peptides. About the water itself: bacteriostatic water.

Storing HGH Fragment 176-191 vials

• Freeze-dried (lyophilized) peptide keeps far longer than peptide in solution; peptide suppliers advise storing the powder at -20°C away from bright light. ^[7]
• Protect peptide vials from heat and light. ^[7][8]
• Avoid repeated freeze-thaw cycles; a prescription peptide label also says not to freeze a vial once it has been mixed. ^[6][7]
• Once a multi-dose vial, such as bacteriostatic water, has been opened (needle-punctured), date it and discard it within 28 days unless its manufacturer states another date. ^[9][10]

More detail: peptide storage and shelf life.

Injecting safely

• Clean the injection site with an alcohol swab and let the skin dry completely before injecting. ^[11][12]
• Pinch up a fold of skin and fat (not muscle) and insert the needle at a 45- to 90-degree angle: 90 degrees where there is enough fatty tissue, 45 degrees where there is little. ^[11][12][13]
• Pulling back on the plunger (aspiration) is not necessary for a subcutaneous injection, because the chance of the needle being in a blood vessel is small. ^[11]
• Inject slowly, at roughly 10 seconds per mL. ^[11]
• Common sites are the belly, the thigh and the upper arm; rotate sites, keeping each injection at least 1 inch (2.5 cm) from the last. ^[6][11][12]

Hygiene and warning signs

• Use a new sterile needle and syringe for every injection and every time you enter a vial; never reuse them. ^[5][9][12]
• Never share needles, syringes or pens with anyone, even if the needle is changed; unsafe injection practices spread hepatitis B, hepatitis C and HIV. ^[5][8][9]
• Put used needles and syringes in a sharps disposal container straight away (FDA-cleared if possible), never loose in the trash, recycling or toilet, and dispose of the container following your community's guidelines. ^[14][15]
• Contact a health care provider if the injection site shows signs of infection, such as redness, swelling, red streaks or a fever. ^[12]

Where to inject: subcutaneous injection sites.

How HGH Fragment 176-191 works

• HGH Fragment 176-191 is a synthetic 16-amino-acid peptide matching amino acids 176-191 at the C-terminal end of human growth hormone. A 1978 study tested it in rats alongside five other synthetic C-terminal fragments of growth hormone. ^[16]
• It is not the same molecule as AOD-9604, which is growth hormone amino acids 177-191 with an extra tyrosine added at the N-terminus. ^[16][17]
• The fat-loss rationale comes from work on the overlapping 177-191 sequence (AOD9401). In isolated rat fat tissue it stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase, as intact growth hormone does. That work did not test the 176-191 sequence itself. ^[18]

What the HGH Fragment 176-191 research found

Human evidence: animal / lab only. Each result says what was studied.

• Animal studyIn the 1978 study in normal rats, 176-191 was one of four growth hormone fragments that caused a short-lived rise in blood glucose and a longer rise in plasma insulin. The two shortest fragments, 179-191 and 180-191, had no effect. ^[16]
• Animal studyIn the same study, a single dose of 5 nmol/kg of the fragments containing the 178-191 sequence, a group that includes 176-191, significantly reduced the rats' insulin sensitivity in intravenous insulin tolerance tests. ^[16]
• Lab studyA 2022 laboratory study loaded fragment 176-191 with the chemotherapy drug doxorubicin into chitosan nanoparticles. The combination slowed the growth of MCF-7 breast cancer cells more than doxorubicin nanoparticles alone. The study did not look at fat loss. ^[19]

HGH Fragment 176-191 side effects and risks

I could not find a published human study of the 176-191 sequence, so there is no human safety data; the only safety-relevant finding is from rats.

• Animal studyIn rats, the fragment acted in the diabetes-like direction: blood glucose rose briefly, plasma insulin stayed raised for longer and insulin sensitivity fell after a single dose. ^[16]

Other things to know

• No published human trial exists for this exact sequence, so there is no human safety, dosing or side-effect record to draw on - the limited safety picture reported for AOD-9604 does not automatically transfer to a related but molecularly different peptide.
• Routinely sold and marketed by conflating it with AOD-9604, a molecule with an added tyrosine and its own (failed) Phase IIb obesity trial; a buyer researching one compound's history may be reading about a substance that is not, molecularly, the one in the vial.
• The only controlled animal data specific to this exact sequence - a 1978 rat study - reported a hyperglycemic action and a rise in plasma insulin, the opposite metabolic direction from the effect it is marketed for today.
• Sold through the same research-chemical and grey-market channels as AOD-9604 and GLP-1 lookalike products, with none of the manufacturing or purity oversight an approved drug requires, and no established human half-life or dosing interval in the literature I could verify.

Reported side effects and what the studies measured: HGH Fragment 176-191 side effects.

Where this vial size comes from

HGH Fragment 176-191 is sold as a 5 mg vial by the pages below, each checked on the date shown. I list them as evidence that this size exists, not as a recommendation to buy from them.

• Next Level PharmvendorLists it as: Size dropdown lists 1mg, 2mg, 5mg, 10mg, 12mg, 15mg vials · checked 2026-09-28
• Peptide Source HubvendorLists it as: "Strength: 5 mg per vial"; 10 vials/kit (50 mg total peptide content) · checked 2026-09-28

The doses come from the sourced common protocol on the HGH Fragment 176-191 dosing page, and every number on this page is arithmetic on those doses and this vial size.

Where to buy HGH Fragment 176-191 for research

Sold for research use only. Listed by Next Level Pharm; compare them on my vendors page or see the listing on the HGH Fragment 176-191 page.

Questions

How much water do I add to a 5 mg HGH Fragment 176-191 vial?

There is no single correct amount: water changes how many units a dose is, not how many doses the vial holds. With 1 mL the vial is 5 mg/mL and 350 mcg is 7 units (0.07 mL) on a U-100 insulin syringe. The units table gives 1, 2, 5 mL.

How many doses are in a 5 mg HGH Fragment 176-191 vial?

25 doses at 200 mcg, 14 doses at 350 mcg, 10 doses at 500 mcg.

How long does a 5 mg HGH Fragment 176-191 vial last?

At 350 mcg a dose and once or twice daily, about 1-2 weeks. How long a mixed vial keeps is a separate limit; see storage below.

How many 5 mg vials do I need for a cycle?

2 vials at 200 mcg 7 times a week for 4 weeks; 17 vials at 500 mcg 14 times a week for 12 weeks.

What does 1 unit equal in a 5 mg HGH Fragment 176-191 vial?

50 mcg with 1 mL, 25 mcg with 2 mL, 10 mcg with 5 mL of bacteriostatic water, on a U-100 syringe.